GemPharmatech Co., Ltd.

688046

CNE100005964

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
11.61 ^CNY	+1.75%		-0.34%	-42.38%

04-26	GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-03	Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023.	CI

GemPharmatech Co., Ltd.(XSSC:688046) added to S&P Global BMI Index

September 18, 2023 at 05:00 am

Latest news about GemPharmatech Co., Ltd.

GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023.	04-03	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Correction: GemPharmatech Responds to US Legislation Concerns	01-30	MT
GemPharmatech Responds to US Legislation Concerns	01-29	MT
China's MGI Tech, GemPharmatech defend themselves after US bill proposed	01-28	RE
Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023.	01-04	CI
GemPharmatech Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares.	12-26	CI
GemPharmatech Co., Ltd. authorizes a Buyback Plan.	12-24	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
GemPharmatech Appoints Board Chairman	20/10/23	MT
GemPharmatech Co., Ltd.(XSSC:688046) added to S&P Global BMI Index	18/09/23	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
GemPharmatech Co., Ltd. Introduced NeoMab	22/08/23	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
GemPharmatech Co., Ltd.(SHSE:688046) added to Shanghai Stock Exchange Composite Index	25/04/23	CI
GemPharmatech Co., Ltd.(SHSE:688046) added to Shanghai Stock Exchange A Share Index	25/04/23	CI
GemPharmatech to Establish 20 Million Yuan Subsidiary; Shares Drop 3%	20/04/23	MT
Gempharmatech Llc announced that it expects to receive $29 million in funding from GemPharmatech Co., Ltd.	17/04/23	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	19/08/22	CI
GemPharmatech announced that it has received $23.32 million in funding from CDH Investments, Sinopharm Group Co. Ltd.	01/07/19	CI

GemPharmatech Co Ltd, formerly Jiangsu Jicui Yaokang Biotechnology Co Ltd, is a China-based company principally engaged in the research, development, production and sales of experimental mouse models. The Company uses gene-editing and other technologies to produce mouse models. The Company also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Companyâs products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Sector

Biotechnology & Medical Research

Calendar

18/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for GemPharmatech Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.61 CNY

Average target price

21.13 CNY

Spread / Average Target

+82.03%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GEMPHARMATECH CO., LTD.	-42.38%	657M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research